When Intimacy Hurts: Dyspareunia in Genitourinary Syndrome of Menopause - A Review of Treatment Options
DOI:
https://doi.org/10.12775/QS.2026.49.67614Keywords
dyspareunia, menopause, genitourinary syndrome of menopauseAbstract
Dyspareunia, defined as pain during or immediately after sexual intercourse, is one of the most common and troublesome symptoms of Genitourinary syndrome of menopause (GSM), affecting a significant number of perimenopausal and postmenopausal women. This paper aims to review and systematize knowledge on pharmacological and non-pharmacological methods of treating this condition, the main cause of which is atrophy of the vulvar and vaginal tissues resulting from estrogen deficiency. An analysis of the available literature indicates that local estrogen therapy remains the gold standard for alleviating symptoms, as it effectively restores the elasticity and lubrication of the epithelium. As alternative therapeutic options, particularly important for patients with contraindications to estrogens, the use of prasterone (DHEA) and oral ospemifene (SERM) is discussed. The paper also presents the role of non-hormonal methods, such as commonly used lubricants and moisturizers as first-line therapy, and hyaluronic acid injections. Attention was also paid to modern laser therapy, which, despite its promising regenerative effects, has not yet been fully approved by scientific societies due to the lack of long-term safety data. The conclusions of the paper emphasise the need for individualised therapy, taking into account the patient's medical history and preferences, which is key to improving the quality of sexual life for women during menopause.
References
1. Fernández-Pérez, P., Leirós-Rodríguez, R., Marqués-Sánchez, M. P., Martínez-Fernández, M. C., de Carvalho, F. O., & Maciel, L. Y. S. (2023). Effectiveness of physical therapy interventions in women with dyspareunia: a systematic review and meta-analysis. BMC women's health, 23(1), 387. https://doi.org/10.1186/s12905-023-02532-8
2. Tayyeb, M., & Gupta, V. (2023). Dyspareunia. In StatPearls. StatPearls Publishing.
3. Managing genitourinary symptoms (network meta-analyses): Menopause: identification and management. (2024). National Institute for Health and Care Excellence (NICE).
4. Tiwari, M., Acharya, N., & Mahakarkar, M. (2025). Navigating the Vaginal Milieu During Perimenopause: A Narrative Review of Physiological Changes and Clinical Implications. Journal of pharmacy & bioallied sciences, 17(Suppl 1), S92–S95. https://doi.org/10.4103/jpbs.jpbs_1493_24
5. Șerbănescu, L., Mirea, S., Ionescu, P., Petrica, L. A., Iorga, I. C., Surdu, M., Surdu, T. V., & Rotar, V. (2025). Involuntary Urine Loss in Menopause-A Narrative Review. Journal of clinical medicine, 14(21), 7664. https://doi.org/10.3390/jcm14217664
6. Danan, E. R., Sowerby, C., Ullman, K. E., Ensrud, K., Forte, M. L., Zerzan, N., Anthony, M., Kalinowski, C., Abdi, H. I., Friedman, J. K., Landsteiner, A., Greer, N., Nardos, R., Fok, C., Dahm, P., Butler, M., Wilt, T. J., & Diem, S. (2024). Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. Annals of internal medicine, 177(10), 1400–1414. https://doi.org/10.7326/ANNALS-24-00610
7. Farahat, R. A., Salamah, H. M., Mahmoud, A., Hamouda, E., Hashemy, M., Hamouda, H., Samir, A., Chenfouh, I., Marey, A., Awad, D. M., Farag, E., Abd-Elgawad, M., & Eldesouky, E. (2023). The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis. BMC women's health, 23(1), 494. https://doi.org/10.1186/s12905-023-02645-0
8. Danan, E. R., Sowerby, C., Ullman, K. E., Ensrud, K., Forte, M. L., Zerzan, N., Anthony, M., Kalinowski, C., Abdi, H. I., Friedman, J. K., Landsteiner, A., Greer, N., Nardos, R., Fok, C., Dahm, P., Butler, M., Wilt, T. J., & Diem, S. (2024). Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. Annals of internal medicine, 177(10), 1400–1414. https://doi.org/10.7326/ANNALS-24-00610
9. Sacarin, G., Abu-Awwad, A., Razvan, N., Craina, M., Hogea, B., Sorop, B., Abu-Awwad, S. A., Diaconu, M., Pilut, N. C., & Suba, M. I. (2025). Sexual Quality of Life in Postmenopausal Women: A Comparative Randomized Controlled Trial of Intravaginal PRP Therapy Versus Local Hormonal Treatments. Medicina (Kaunas, Lithuania), 61(7), 1140. https://doi.org/10.3390/medicina61071140
10. Ali, A., Iftikhar, A., Tabassum, M., Imran, R., Shaid, M. U., Hashmi, M. R., Saad, M., Humayun, M., Imtiaz, S., & Baig, E. (2024). Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis. Journal of menopausal medicine, 30(2), 88–103.
11. Cuccu, I., Golia D'Augè, T., Firulli, I., De Angelis, E., Buzzaccarini, G., D'Oria, O., Besharat, A. R., Caserta, D., Bogani, G., Muzii, L., Di Donato, V., & Giannini, A. (2024). Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach. Life (Basel, Switzerland), 14(11), 1504. https://doi.org/10.3390/life14111504
12. Lara, L. A., Cartagena-Ramos, D., Figueiredo, J. B., Rosa-E-Silva, A. C. J., Ferriani, R. A., Martins, W. P., & Fuentealba-Torres, M. (2023). Hormone therapy for sexual function in perimenopausal and postmenopausal women. The Cochrane database of systematic reviews, 8(8), CD009672. https://doi.org/10.1002/14651858.CD009672.pub3
13. Thurman, A., Hull, M. L., Stuckey, B., Hatheway, J., Zack, N., Mauck, C., & Friend, D. (2023). A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women. Menopause (New York, N.Y.), 30(9), 940–946. https://doi.org/10.1097/GME.0000000000002230
14. Valdes, A., Patel, P., & Bajaj, T. (2025). Estrogen Therapy. In StatPearls. StatPearls Publishing.
15. Fedotcheva, T. A., Uspenskaya, M. E., Ulchenko, D. N., & Shimanovsky, N. L. (2024). Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application. Pharmaceuticals (Basel, Switzerland), 17(9), 1186. https://doi.org/10.3390/ph17091186
16. Musbahi, E., Kamp, E., Ashraf, M., & DeGiovanni, C. (2022). Menopause, skin and common dermatosis. Part 3: genital disorders. Clinical and experimental dermatology, 47(12), 2123–2129. https://doi.org/10.1111/ced.15400
17. Lin, H. Y., Chen, J. H., & Chen, K. H. (2025). The Sex Hormone Precursors Dehydroepiandrosterone (DHEA) and Its Sulfate Ester Form (DHEAS): Molecular Mechanisms and Actions on Human Body. International journal of molecular sciences, 26(17), 8568. https://doi.org/10.3390/ijms26178568
18. Benini, V., Ruffolo, A. F., Casiraghi, A., Degliuomini, R. S., Frigerio, M., Braga, A., Serati, M., Torella, M., Candiani, M., & Salvatore, S. (2022). New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. Medicina (Kaunas, Lithuania), 58(6), 770. https://doi.org/10.3390/medicina58060770
19. Shim, S., Park, K. M., Chung, Y. J., & Kim, M. R. (2021). Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. Journal of menopausal medicine, 27(1), 1–7. https://doi.org/10.6118/jmm.20034
20. Simon, J. A., Ferenczy, A., Black, D., Castonguay, A., Royer, C., Marouf, R., & Beauchemin, C. (2023). Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. Menopause (New York, N.Y.), 30(8), 855–866. https://doi.org/10.1097/GME.0000000000002211
21. Marchetti, G., Taithongchai, A., & Robinson, D. (2024). Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection. International journal of women's health, 16, 1049–1053. https://doi.org/10.2147/IJWH.S431520
22. Nappi, R. E., Martella, S., Albani, F., Cassani, C., Martini, E., & Landoni, F. (2022). Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?. Healthcare (Basel, Switzerland), 10(8), 1528. https://doi.org/10.3390/healthcare10081528
23. Ospemifene (Osphena): CADTH Reimbursement Recommendation. (2022). Canadian Agency for Drugs and Technologies in Health.
24. Bensmail, H., Marchand Lamiraud, F., Martin, C., Pelckmans, S., Cha'ban, F., Siboni Frisch, A., Deniz, G., Sabban Serfati, P., Caubo, B., Gurriet, B., Petit Breuilh, I., Pastijn, A. I., Berreni, N., & Cosson, M. (2025). Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women: A 52-week long-term follow-up. Maturitas, 201, 108687. https://doi.org/10.1016/j.maturitas.2025.108687
25. Marchand Lamiraud, F., Bensmail, H., Martin, C., Pelckmans, S., Cha'ban, F., Siboni Frisch, A., Deniz, G., Sabban Serfati, P., Caubo, B., Gurriet, B., Petit Breuilh, I., Pastijn, A. I., Berreni, N., & Cosson, M. (2025). Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy in postmenopausal women: A 12-week randomised, placebo-controlled, multicentric study. Maturitas, 197, 108264. https://doi.org/10.1016/j.maturitas.2025.108264
26. Albalawi, N. S., Almohammadi, M. A., & Albalawi, A. R. (2023). Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review. Cureus, 15(8), e44191. https://doi.org/10.7759/cureus.44191
27. Agrawal, S., LaPier, Z., Nagpal, S., Oot, A., Friedman, S., Hade, E. M., Nachtigall, L., Brucker, B. M., & Escobar, C. (2024). A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause (New York, N.Y.), 31(9), 750–755. https://doi.org/10.1097/GME.0000000000002390
28. Pessoa, L. L. M. N., de Souza, A. T. B., Sarmento, A. C. A., Ferreira Costa, A. P., Kelly Dos Santos, I., Pereira de Azevedo, E., de Medeiros, K. S., Gonçalves, A. K., & Cobucci, R. N. (2024). Laser therapy for genitourinary syndrome of menopause: systematic review and meta-analysis of randomized controlled trial. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 46, e-rbgo38. https://doi.org/10.61622/rbgo/2024rbgo38
29. Kershaw, V., & Jha, S. (2024). Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms. International journal of women's health, 16, 1909–1938. https://doi.org/10.2147/IJWH.S446903
30. Zipper, R., & Lamvu, G. (2022). Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here. Journal of comparative effectiveness research, 11(11), 843–851. https://doi.org/10.2217/cer-2021-0281
31. Prodromidou, A., Zacharakis, D., Athanasiou, S., Kathopoulis, N., Varthaliti, A., Douligeris, A., Michala, L., Athanasiou, V., Salvatore, S., & Grigoriadis, T. (2023). CO2 Laser versus Sham Control for the Management of Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of personalized medicine, 13(12), 1694. https://doi.org/10.3390/jpm13121694
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Julia Dąbrowska, Michał Białogłowski, Katarzyna Mazurek, Anna Gęborys, Maja Wojcieszak, Julia Matuszewska, Weronika Woźnica, Alicja Maziarczyk, Jakub Lambach, Dominika Miazga

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 33
Number of citations: 0